Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J. van der Horst, Tuna Mutis, Ida H. Hiemstra et al.|Blood Cancer Journal|2021Cited by 95
Distinct peripheral T-cell and NK-cell profiles in HGBL-<i>MYC/BCL2</i> vs patients with DLBCL NOSA. Vera de Jonge, Tuna Mutis|Blood Advances|2024Cited by 9